Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing Klebsiella pneumoniae Bacteremia and Renal Impairment

Pharmacotherapy

Volumn 36, Issue 11, 2016, Pages e172-e177

  Veillette, John J ^a   Truong, James ^a   Forland, Steven C ^a,b,c  

^a LOMA LINDA UNIVERSITY   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

avibactam; ceftazidime; Klebsiella pneumoniae; KPC; obesity; pharmacokinetics; renal impairment

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIKACIN; AMOXICILLIN; ASPARTATE AMINOTRANSFERASE; AVIBACTAM PLUS CEFTAZIDIME; BILIRUBIN; CARBAPENEMASE; CEFEPIME; CLINDAMYCIN; COTRIMOXAZOLE; CREATININE; DAPTOMYCIN; ELECTROLYTE; GLUCOSE; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; PHOSPHATE; PROCALCITONIN; UNCLASSIFIED DRUG; UREA; VANCOMYCIN; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFTAZIDIME;

ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CASE REPORT; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; END STAGE RENAL DISEASE; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; JEJUNOSTOMY; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; NECROTIZING FASCIITIS; OBESITY; SINGLE DRUG DOSE; STEADY STATE; BACTEREMIA; COMPLICATION; HALF LIFE TIME; ISOLATION AND PURIFICATION; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIOLOGY; MORBID OBESITY; TISSUE DISTRIBUTION;

ADULT; AGED; AZABICYCLO COMPOUNDS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; FEMALE; HALF-LIFE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; OBESITY, MORBID; RENAL INSUFFICIENCY; TISSUE DISTRIBUTION;

EID: 84995801545     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1840     Document Type: Article

References (27)

1. Forest Pharmaceuticals. AVYCAZ I.V. (ceftazidime-avibactam for injection) package insert. Cincinnati, OH; 2015.
2. Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 2014;9:13–25.
3. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 2014;58(2):833–8.
4. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother 2013;68(5):1183–92.
5. Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012;28(12):1921–31.
6. Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig 2015;35(5):307–17.
7. Demirovic JA, Pai AB, Pai MP. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66(7):642–8.
8. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which use multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976;4:183–95.
9. Xu A. Validation report on an analytical procedure for the quantification of ceftazidime and avibactam in human NaF/KOX plasma by LC/MS/MS. North Wales, PA: Keystone Bioanalytical, 2015.
10. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25(4):433–7.
11. Plantier J, Forrey AW, O'Neill MA, Blair AD, Christopher TG, Cutler RE. Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay. J Infect Dis 1976;134(Suppl):S323–30.
12. McHenry MC, Wagner JG, Hall PM, Vidt DG, Gavan TL. Pharmacokinetics of amikacin in patients with impaired renal function. J Infect Dis 1976;134(Suppl):S343–8.
13. Welage LS, Schultz RW, Schentag JJ. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Antimicrob Agents Chemother 1984;25(2):201–4.
14. Louie A, Castanheira M, Liu W, et al. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob Agents Chemother 2012;56(1):258–70.
15. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011;55(1):82–5.
16. Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother 2014;58(6):3366–72.
17. Li J, Zhou D, Nichols W, Das S. Abstr 52nd Intersci Conf Antimicrob Agents Chemother 2012, San Francisco, CA. Abstract A-635. Evaluation of ceftazidime-avibactam (CAZ-AVI) dose regimens for Phase III study in patients with different renal function.
18. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002;50(3):425–8.
19. Aitken SL, Altshuler J, Guervil DJ, et al. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents 2015;45(5):541–4.
20. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007;51(5):1725–30.
21. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008;31(4):345–51.
22. Tam VH, Schilling AN, Neshat S, Poole K, Melnick DA, Coyle EA. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49(12):4920–7.
23. Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014;58(8):1072–83.
24. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother 2015;59(6):3509–17.
25. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014;58(4):2322–8.
26. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55(7):943–50.
27. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17(12):1798–803.